Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives

Author(s): Antonio Marra, Cristina R. Ferrone, Celeste Fusciello, Giosue Scognamiglio, Soldano Ferrone, Stefano Pepe, Francesco Perri, Francesco Sabbatino*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 18 , Issue 2 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Melanoma is an aggressive form of skin cancer characterized by poor prognosis and high mortality. The development of targeted agents based on the discovery of driver mutations as well as the implementation of checkpoint inhibitor-based immunotherapy represents a major breakthrough in the treatment of metastatic melanoma. However, in both cases the development of drug resistance and immune escape mechanisms as well as the lack of predictive biomarkers limits their extraordinary clinical efficacy. In this article, we summarize the available therapeutic options for patients with metastatic melanoma, outline the mechanisms implicated in the resistance to both targeted agents and immunotherapy, discuss potential predictive biomarkers and outline future therapeutic approaches under investigation.

Keywords: Melanoma, targeted therapy, immunotherapy, immune checkpoint molecules, PD-1, PD-L1, BRAF inhibitor resistance, immunotherapy resistance, predictive biomarkers.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [166 - 181]
Pages: 16
DOI: 10.2174/1871520618666171219115335
Price: $65

Article Metrics

PDF: 41
HTML: 10
PRC: 1